HRP980095A2 - Method of treating a tumor - Google Patents
Method of treating a tumorInfo
- Publication number
- HRP980095A2 HRP980095A2 HR08/814,769A HRP980095A HRP980095A2 HR P980095 A2 HRP980095 A2 HR P980095A2 HR P980095 A HRP980095 A HR P980095A HR P980095 A2 HRP980095 A2 HR P980095A2
- Authority
- HR
- Croatia
- Prior art keywords
- paclitaxel
- tumor
- tirapazamine
- carboplatin
- oxaliplatin
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 88
- 238000000034 method Methods 0.000 title claims abstract description 14
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims abstract description 48
- 229960001592 paclitaxel Drugs 0.000 claims abstract description 47
- ORYDPOVDJJZGHQ-UHFFFAOYSA-N tirapazamine Chemical compound C1=CC=CC2=[N+]([O-])C(N)=N[N+]([O-])=C21 ORYDPOVDJJZGHQ-UHFFFAOYSA-N 0.000 claims abstract description 47
- 229930012538 Paclitaxel Natural products 0.000 claims abstract description 46
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims abstract description 46
- 229910052697 platinum Inorganic materials 0.000 claims abstract description 23
- 241000124008 Mammalia Species 0.000 claims abstract description 17
- 238000011282 treatment Methods 0.000 claims abstract description 17
- 229960004562 carboplatin Drugs 0.000 claims description 33
- 229960001756 oxaliplatin Drugs 0.000 claims description 22
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical group O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 19
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 17
- 229960004316 cisplatin Drugs 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 5
- 190000008236 carboplatin Chemical compound 0.000 claims 4
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- 229950002376 tirapazamine Drugs 0.000 description 50
- 241000699670 Mus sp. Species 0.000 description 25
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 25
- 230000009467 reduction Effects 0.000 description 16
- 239000003795 chemical substances by application Substances 0.000 description 14
- 239000002246 antineoplastic agent Substances 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 206010021143 Hypoxia Diseases 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 230000001146 hypoxic effect Effects 0.000 description 7
- 208000020816 lung neoplasm Diseases 0.000 description 7
- BNZPFJBUHRBLNB-UHFFFAOYSA-N 1-oxido-1,2,4-benzotriazin-1-ium Chemical class C1=CC=C2[N+]([O-])=NC=NC2=C1 BNZPFJBUHRBLNB-UHFFFAOYSA-N 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 208000037841 lung tumor Diseases 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 102000029749 Microtubule Human genes 0.000 description 5
- 108091022875 Microtubule Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 229940100198 alkylating agent Drugs 0.000 description 5
- 239000002168 alkylating agent Substances 0.000 description 5
- 210000004688 microtubule Anatomy 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000005855 radiation Effects 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 150000003057 platinum Chemical class 0.000 description 4
- -1 platinum coordination complex Chemical class 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 230000003442 weekly effect Effects 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 231100000599 cytotoxic agent Toxicity 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 101710112752 Cytotoxin Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 239000002619 cytotoxin Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 239000008355 dextrose injection Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 201000005296 lung carcinoma Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
- 229960001924 melphalan Drugs 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000008389 polyethoxylated castor oil Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000008354 sodium chloride injection Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 2
- 238000013414 tumor xenograft model Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 241000006334 Phyllosma Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 240000006474 Theobroma bicolor Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229940044684 anti-microtubule agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000001370 bioreducing effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 150000003058 platinum compounds Chemical class 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000002534 radiation-sensitizing agent Substances 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81476997A | 1997-03-07 | 1997-03-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP980095A2 true HRP980095A2 (en) | 1998-12-31 |
Family
ID=25215967
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR08/814,769A HRP980095A2 (en) | 1997-03-07 | 1998-02-25 | Method of treating a tumor |
Country Status (15)
Country | Link |
---|---|
US (2) | US6063780A (de) |
EP (1) | EP1014990B1 (de) |
JP (1) | JP2001513110A (de) |
AT (1) | ATE338553T1 (de) |
AU (1) | AU6178198A (de) |
BR (1) | BR9808221A (de) |
CA (1) | CA2281807C (de) |
DE (1) | DE69835824T2 (de) |
DK (1) | DK1014990T3 (de) |
ES (1) | ES2268764T3 (de) |
HR (1) | HRP980095A2 (de) |
NO (1) | NO324974B1 (de) |
PT (1) | PT1014990E (de) |
WO (1) | WO1998039009A1 (de) |
ZA (1) | ZA981609B (de) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1014990B1 (de) * | 1997-03-07 | 2006-09-06 | Sanofi-Aventis U.S. LLC | Antitumorkombination aus 3-amino-1,2,4-benzotriazine 1,4-dioxid/paclitaxel/platin |
WO2000021527A2 (fr) | 1998-10-14 | 2000-04-20 | Debiopharm S.A. | Conditionnement d'une preparation d'oxaliplatine |
DE19925211B4 (de) * | 1999-06-01 | 2006-01-12 | PBS Pharmaceutical Bulk Substances SA | Kit zur Herstellung einer Formulierung von Paclitaxel |
BRPI0013613B8 (pt) * | 1999-08-30 | 2021-05-25 | Debiopharm Sa | composição farmacêuticamente estável de oxaliplatina para administração parenteral. |
US7070796B1 (en) | 1999-08-30 | 2006-07-04 | Debiopharm S.A. | Pharmaceutically stable oxaliplatinum preparation for parenteral administration |
US7012072B2 (en) | 2000-12-12 | 2006-03-14 | Debiopharm S.A. | Pharmaceutical oxaliplatinum preparation for parenteral administration and method for obtaining same |
US6476068B1 (en) | 2001-12-06 | 2002-11-05 | Pharmacia Italia, S.P.A. | Platinum derivative pharmaceutical formulations |
WO2004012746A2 (en) * | 2002-08-02 | 2004-02-12 | The Regents Of The University Of California | New uses for inhibitors of inosine monophosphate dehydrogenase |
AU2003239511A1 (en) * | 2003-05-20 | 2004-12-13 | Aronex Pharmaceuticals, Inc. | Combination chemotherapy comprising a liposomal platinum complex |
US7989490B2 (en) * | 2004-06-02 | 2011-08-02 | Cordis Corporation | Injectable formulations of taxanes for cad treatment |
US20060275331A1 (en) * | 2004-08-31 | 2006-12-07 | Borek Zaludek | Pharmaceutical composition, method of manufacturing and therapeutic use thereof |
JP2006248978A (ja) | 2005-03-10 | 2006-09-21 | Mebiopharm Co Ltd | 新規なリポソーム製剤 |
US20090136521A1 (en) * | 2005-10-03 | 2009-05-28 | Genetix Pharmaceuticals , Inc. | Method for Selectively Depleting Hypoxic Cells |
US20070212360A1 (en) * | 2006-01-17 | 2007-09-13 | Denko Nicholas C | Modulation of mitochondrial oxygen consumption for therapeutic purposes |
US8026017B2 (en) | 2007-03-16 | 2011-09-27 | The United States Of America As Represented By The Secretary Of The Army | High voltage methanol fuel cell assembly using proton exchange membranes and base/acid electrolytes |
WO2009126705A2 (en) | 2008-04-10 | 2009-10-15 | Virginia Commonwealth University | Induction of tumor hypoxia for cancer therapy |
US9278124B2 (en) | 2012-10-16 | 2016-03-08 | Halozyme, Inc. | Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods |
EP4201403A1 (de) * | 2021-12-21 | 2023-06-28 | Som Innovation Biotech, S.L. | Verbindungen tirapazamin und quazinon zur verwendung bei der behandlung von gm2-gangliosidosen |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5399363A (en) * | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
US5484612A (en) * | 1993-09-22 | 1996-01-16 | The Board Of Trustees Of The Leland Stanford Junior University | Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin |
EP1014990B1 (de) * | 1997-03-07 | 2006-09-06 | Sanofi-Aventis U.S. LLC | Antitumorkombination aus 3-amino-1,2,4-benzotriazine 1,4-dioxid/paclitaxel/platin |
-
1998
- 1998-02-17 EP EP98906594A patent/EP1014990B1/de not_active Expired - Lifetime
- 1998-02-17 AU AU61781/98A patent/AU6178198A/en not_active Abandoned
- 1998-02-17 ES ES98906594T patent/ES2268764T3/es not_active Expired - Lifetime
- 1998-02-17 DK DK98906594T patent/DK1014990T3/da active
- 1998-02-17 CA CA002281807A patent/CA2281807C/en not_active Expired - Fee Related
- 1998-02-17 WO PCT/US1998/003292 patent/WO1998039009A1/en active IP Right Grant
- 1998-02-17 JP JP53855198A patent/JP2001513110A/ja not_active Ceased
- 1998-02-17 PT PT98906594T patent/PT1014990E/pt unknown
- 1998-02-17 BR BR9808221-3A patent/BR9808221A/pt not_active Application Discontinuation
- 1998-02-17 DE DE69835824T patent/DE69835824T2/de not_active Expired - Fee Related
- 1998-02-17 AT AT98906594T patent/ATE338553T1/de not_active IP Right Cessation
- 1998-02-25 HR HR08/814,769A patent/HRP980095A2/hr not_active Application Discontinuation
- 1998-02-26 ZA ZA981609A patent/ZA981609B/xx unknown
- 1998-02-27 US US09/031,692 patent/US6063780A/en not_active Expired - Fee Related
-
1999
- 1999-09-06 NO NO19994330A patent/NO324974B1/no unknown
-
2000
- 2000-02-16 US US09/505,043 patent/US6319923B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP1014990A4 (de) | 2004-03-24 |
CA2281807C (en) | 2007-10-16 |
US6319923B1 (en) | 2001-11-20 |
DE69835824T2 (de) | 2007-03-29 |
ES2268764T3 (es) | 2007-03-16 |
CA2281807A1 (en) | 1998-09-11 |
EP1014990A1 (de) | 2000-07-05 |
ZA981609B (en) | 1998-12-08 |
PT1014990E (pt) | 2006-11-30 |
DK1014990T3 (da) | 2006-12-11 |
ATE338553T1 (de) | 2006-09-15 |
JP2001513110A (ja) | 2001-08-28 |
AU6178198A (en) | 1998-09-22 |
US6063780A (en) | 2000-05-16 |
NO324974B1 (no) | 2008-01-14 |
BR9808221A (pt) | 2000-05-16 |
NO994330L (no) | 1999-10-25 |
NO994330D0 (no) | 1999-09-06 |
WO1998039009A1 (en) | 1998-09-11 |
EP1014990B1 (de) | 2006-09-06 |
DE69835824D1 (de) | 2006-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP980095A2 (en) | Method of treating a tumor | |
KR100598474B1 (ko) | 항종양제 | |
Koukourakis | Amifostine in clinical oncology: current use and future applications | |
US6610699B2 (en) | Use of L-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity | |
Pierson et al. | Sodium ascorbate enhancement of carbidopa-levodopa methyl ester antitumor activity against pigmented B16 melanoma | |
CA2286557A1 (en) | Phorbol esters as anti-neoplastic agents | |
JP2011506467A (ja) | 抗悪性腫瘍性熱ショックアポトーシス活性化因子(hsaa)と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法 | |
US6548531B2 (en) | Method for cancer therapy | |
Brunsvig et al. | Weekly docetaxel with concurrent radiotherapy in locally advanced non-small cell lung cancer: A Phase I/II study with 5 years’ follow-up | |
Theriault et al. | Use of Taxol (paclitaxel) in breast cancer | |
CA2370600A1 (en) | Use of antioxidants to mitigate radioimmunotherapy-induced radiation toxicity | |
RU2005132175A (ru) | Комбинированное лечение опухолей, включающее неморубицин и лучевую терапию | |
KR20210039413A (ko) | 암의 치료를 위한 병용 요법 | |
KR20210039414A (ko) | 암의 치료를 위한 병용 요법 | |
RU2678103C2 (ru) | Противоопухолевое средство, содержащее противоопухолевый комплекс платины, и усилитель противоопухолевого эффекта | |
RU2392935C1 (ru) | Способ сочетанного консервативного воздействия на злокачественные опухоли | |
CN111407748B (zh) | 酪醇在制备治疗脑胶质瘤的药物中的应用 | |
RU2195937C1 (ru) | Комбинированный противотуберкулезный препарат (ризобутол) | |
MX2010004437A (es) | Composicion de yodo molecular de uso humano para la prevencion y tratamiento de patalogias prostaticas. | |
MXPA99008176A (en) | Method of treating a tumor | |
RU2495665C2 (ru) | Способ повышения чувствительности животных к радиоактивному облучению | |
CN103889222A (zh) | 含有紫杉醇乳清酸酯的药物组合物 | |
JP2006518355A (ja) | インドロピロロカルバゾール誘導体及び他の抗腫瘍薬を含む併用療法 | |
JP2008534624A (ja) | インドロキノンによる腫瘍の放射線増感 | |
US20120082736A1 (en) | Small-molecule TNF modulator to reduce the side effects of chemotherapy and radiotherapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
ODBI | Application refused |